Organization

PROGREDUM GMBH

German SME participating in biomedical staff exchange networks focused on cancer therapy, medical imaging, and RNA therapeutics.

Technology SMEhealthDESMEThin data (2/5)

H2020 projects

As coordinator

Total EC funding

€501K

Unique partners

What they do

Their core work

Progredum is a German SME based in Kaiserslautern that serves as a private-sector bridge partner in EU-funded research staff exchange programs focused on health and biomedical sciences. They participate in MSCA-RISE networks that transfer knowledge between academia and industry in areas ranging from health tourism and aging to cancer therapy and advanced medical imaging. Their consistent role across five staff exchange projects suggests they provide industry-side hosting, training infrastructure, or applied research capacity for visiting researchers working on biomedical challenges.

Core expertise

What they specialise in

Cancer diagnostics and monitoringprimary

3 projects

PRISAR2 (rectal cancer surveillance), CANCER (postoperative immunotherapy), and cONCReTE (RNA cancer therapeutics) all address different aspects of cancer management.

Medical imaging and nanomaterialssecondary

2 projects

SENATOR focuses on 19F MRI with perfluorocarbon nanomaterials, while PRISAR2 involves imaging-based cancer monitoring.

Health, aging, and well-beingsecondary

1 project

CHARMED studied green microenvironments and their impact on health, well-being, and aging populations.

RNA-based cancer therapeuticsemerging

1 project

cONCReTE (2020-2025) focuses specifically on development of cancer RNA therapeutics, their most recently started project.

Evolution & trajectory

How they've shifted over time

Early focus

Health and well-being

Recent focus

Cancer therapy and imaging

Progredum entered H2020 in 2017 with broader health and well-being topics — aging, health tourism, and microenvironment research (CHARMED). By 2018-2020, their focus shifted decisively toward oncology: cancer immunotherapy, rectal cancer monitoring, MRI nanomaterials, and RNA therapeutics now dominate their portfolio. This trajectory shows a clear specialization from general health sciences into targeted cancer diagnosis and treatment research.

Progredum is converging on precision oncology — combining advanced imaging, immunotherapy, and RNA therapeutics — making them a relevant partner for cancer-focused consortia needing private-sector participation.

Collaboration profile

How they like to work

Role: specialist_contributorReach: European12 countries collaborated

Progredum operates exclusively as a participant, never coordinating, which is typical for SMEs in MSCA-RISE staff exchange networks where universities usually lead. With 54 unique partners across 12 countries from just 5 projects, they plug into large, internationally diverse consortia. This broad but non-leading pattern suggests they are valued as an accessible industry partner for researcher mobility rather than as a project driver.

Progredum has built a wide network of 54 consortium partners spread across 12 countries through MSCA-RISE staff exchanges. Their base in Kaiserslautern — a city with strong ties to TU Kaiserslautern and the Fraunhofer ecosystem — likely positions them within a broader German research landscape.

Why partner with them

What sets them apart

Progredum fills a specific niche: a German SME that consistently provides private-sector placement capacity in biomedical staff exchange programs. Their portfolio spanning MRI nanomaterials, cancer immunotherapy, and RNA therapeutics gives them unusual cross-disciplinary reach for a small company. For consortium builders needing an industry partner in Germany for MSCA or similar mobility-focused calls, Progredum offers a proven track record of participation.

Notable projects

Highlights from their portfolio

cONCReTE
Their highest-funded project (EUR 110,400) and most forward-looking topic — RNA cancer therapeutics — signals where the company is heading.
PRISAR2
Addresses the clinically significant 'watch and wait' approach to rectal cancer, combining imaging, diagnostics, and active monitoring as alternatives to surgery.
SENATOR
Highly specialized topic — 19F MRI with perfluorocarbon nanomaterials — indicating technical depth in advanced imaging materials.

Cross-sector capabilities

Nanomaterials and advanced materialsMedical imaging technologyBiotechnology and RNA therapeuticsHealth tourism and demographic aging

Analysis note: All 5 projects are MSCA-RISE staff exchanges with relatively small funding (EUR 82-110K each), which limits insight into Progredum's independent capabilities. No website is available for verification. The company's actual products or services outside EU projects remain unclear — they may primarily function as a facilitator for researcher mobility rather than as a technology developer. Profile should be treated as indicative, not definitive.